Planned US-funded baby vaccine trial in Guinea-Bissau blasted by WHO
The World Health Organization (WHO) has criticized a now-halted, US-funded hepatitis B vaccine trial planned for Guinea-Bissau as unethical. The $1.6 million study, involving 14,000 newborns, aimed to compare administering the vaccine at birth versus at six weeks.

Briefing Summary
AI-generatedThe World Health Organization (WHO) has criticized a now-halted, US-funded hepatitis B vaccine trial planned for Guinea-Bissau as unethical. The $1.6 million study, involving 14,000 newborns, aimed to compare administering the vaccine at birth versus at six weeks. The WHO expressed "significant concerns" regarding the study's scientific justification, ethical safeguards, and consistency with established research standards, emphasizing the birth-dose vaccine's proven effectiveness in preventing mother-to-child transmission. The WHO recommends administering the vaccine within 24 hours of birth and argued that withholding the proven vaccine from some newborns exposed them to potential harm. Public outrage in Guinea-Bissau led to the government suspending the trial last month.
Article analysis
Model · rule-basedKey claims
5 extractedThe Guinea-Bissau government suspended the trial last month due to public outrage.
The WHO said giving a proven life-saving intervention to some newborns but not others exposed them to "potentially irreversible harm".
The US-funded study planned to give some newborns the hepatitis B vaccine at birth and others at six weeks.
The WHO criticized a US-funded hepatitis B vaccine trial in Guinea-Bissau as "unethical".
A sizeable portion of Guinea-Bissau's population is estimated to have hepatitis B.